LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference

Core Insights - LB Pharmaceuticals Inc will present at the Stifel 2025 Healthcare Conference on November 13, 2025, at 9:20 a.m. ET [1] - A live webcast of the presentation will be available on the Company's website [2] Product Development - LB-102 is a Phase 3-ready oral small molecule and a methylated derivative of amisulpride, showing positive results in a Phase 2 trial for acute schizophrenia [3] - The Phase 2 trial demonstrated statistically significant benefits versus placebo at all doses, a potentially leading safety profile among D2 antagonists and partial agonists, and positive effects on negative symptoms and cognition [3] - LB-102 is advancing into a Phase 3 clinical trial for acute schizophrenia and a Phase 2 trial for bipolar depression, with potential expansion into major depressive disorder, Alzheimer's disease psychosis, and other conditions [3] Company Overview - LB Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases [4] - The Company aims to leverage the therapeutic potential of LB-102, which could become the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the U.S. [4] - If approved, LB-102 has the potential to be a mainstay in psychiatric practice, offering an attractive alternative to existing treatments [4]